^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:CH4987655 (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Clin Cancer Res
    Title:

    Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

    Excerpt:
    The patient with NRAS-mutant melanoma who experienced PR received study treatment for 323 days.
    DOI:
    10.1158/1078-0432.CCR-14-0341